Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Venetoclax plus Azacitidine versus Standard intensive Chemotherapy for Patients with newly diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations eligible for intensive Treatment (VINCENT)

Next Previous
Search
Trial Profile

Venetoclax plus Azacitidine versus Standard intensive Chemotherapy for Patients with newly diagnosed Acute Myeloid Leukemia (AML) and NPM1 Mutations eligible for intensive Treatment (VINCENT)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mitoxantrone (Primary) ; Venetoclax (Primary) ; Azacitidine; Cytarabine; Daunorubicin; Gemtuzumab ozogamicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms VINCENT

    • Most Recent Events

    • 10 Feb 2025 According to Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition, Currently 18 centers are active.
    • 10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top